[Click eStock] "Vuno, Time for a New Leap Forward"

Daishin Securities analyzed on the 20th that Vuno is the only company within the medical AI sector with guaranteed earnings growth.

Han Song-hyeop, a researcher at Daishin Securities, explained, "Among medical AI companies, it is the only one whose quarterly sales have not declined but have continuously grown," adding, "It has clear growth drivers that can soon be confirmed." He continued, "We believe it can be a representative beneficiary of the growth stock rally driven by interest rate cuts," and added, "This is a turning point for a rebound that can overcome the recent stock price weakness."

The researcher stated, "The core driver of earnings growth is DeepCAS," and analyzed, "It is currently being used in 85 hospitals and is expected to expand to 150 by the end of the year." Furthermore, he emphasized, "Upon achieving the target, a quarterly sales revenue of at least 9 billion KRW from DeepCAS is possible," and "In the second quarter, sales from DeepCAS alone will reach the level of the first quarter."

He explained, "This year's target sales are 26 billion to 30 billion KRW," and "The regular cost structure is about 7.5 billion KRW per quarter, and we expect to turn profitable in the second half of this year." He continued, "The annual break-even point (BEP) sales are expected to be about 30 billion KRW," and predicted, "From next year, it will transform into a stable profitable company."

This content was produced with the assistance of AI translation services.